The New York Times (8/4, A1, Belluck) reported the FDA has approved Zurzuvae (zuranolone), “the first pill for postpartum depression, a milestone considered likely to increase recognition and treatment of” the condition. According to the Times, “Clinical trial data show the pill works quickly, beginning to ease depression in as little as three days, significantly faster than general antidepressants, which can take two weeks or longer to have an effect.”
NBC News (8/4, Bendix, Kopf) reported, “The medication…is taken daily for two weeks.” Researchers found, “in a pair of clinical trials involving women who experienced severe depression after having a baby, the drug improved symptoms – such as anxiety, difficulty sleeping, loss of pleasure, low energy, guilt or social withdrawal – as early as three days after taking the first pill.”
Also covering the story were CNN (8/4, Howard), Reuters (8/5), The Hill (8/4, Robertson), the AP (8/4, Perrone), HealthDay (8/5, Mann), MedPage Today (8/4, Monaco), and Medscape (8/4, Marcus, Subscription Publication).
Related Links:
— “FDA approves first pill for postpartum depression,”Aria Bendix and Marina Kopf, NBC News, August 4, 2023